The market for Lipid-Lowering Agents in EU-27 is a rapidly growing market with several trends and developments.
Customer preferences: The primary customer preference in the EU-27 market for Lipid-Lowering Agents is for drugs that are effective and affordable. Patients in the EU-27 region are increasingly aware of the importance of managing their cholesterol levels, and are seeking drugs that can help them achieve this goal. Additionally, patients are increasingly looking for drugs that have fewer side effects and are easier to administer.
Trends in the market: One of the key trends in the Lipid-Lowering Agents market in EU-27 is the increasing use of statins. Statins are a class of drugs that are used to lower cholesterol levels in the blood. They are highly effective and have been shown to reduce the risk of heart attack and stroke in patients. Another trend in the market is the increasing use of combination therapies. Combination therapies are drugs that combine two or more active ingredients to achieve better results. This trend is driven by the fact that many patients in the EU-27 region have multiple risk factors for heart disease, and require more aggressive treatment.
Local special circumstances: One of the key local special circumstances in the EU-27 market for Lipid-Lowering Agents is the variation in healthcare systems across the region. While some countries have highly developed healthcare systems that provide universal coverage, others have more limited systems that may not cover all patients. This can impact the availability and affordability of Lipid-Lowering Agents in different parts of the region.
Underlying macroeconomic factors: The underlying macroeconomic factors that are driving the growth of the Lipid-Lowering Agents market in EU-27 include an aging population, increasing rates of obesity, and rising levels of income. As the population ages, the incidence of heart disease and other chronic conditions increases, driving demand for Lipid-Lowering Agents. Additionally, as obesity rates continue to rise, more people are at risk of developing heart disease and other related conditions. Finally, rising levels of income in the region are making Lipid-Lowering Agents more affordable and accessible to a larger segment of the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
